Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator
about
Impacts of tissue-type plasminogen activator (tPA) on neuronal survivalPhysiological and pathological roles of tissue plasminogen activator and its inhibitor neuroserpin in the nervous systemTissue-type plasminogen activator is a neuroprotectant in the central nervous systemConformations of tissue plasminogen activator (tPA) orchestrate neuronal survival by a crosstalk between EGFR and NMDAR.Discrepant fibrinolytic response in plasma and whole blood during experimental endotoxemia in healthy volunteersTissue plasminogen activator protects hippocampal neurons from oxygen-glucose deprivation injury.Role of thrombolytic agents in cardiac arrest.Endogenous zinc in neurological diseases.Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activatorTissue plasminogen activator alters intracellular sequestration of zinc through interaction with the transporter ZIP4Serine protease inhibitors: novel therapeutic targets for stroke?PAI-1-derived peptide EEIIMD prevents impairment of cerebrovasodilation by augmenting p38 MAPK upregulation after cerebral hypoxia/ischemia.Angiotensin II potentiates zinc-induced cortical neuronal death by acting on angiotensin II type 2 receptortPA contributes to impairment of ATP and Ca sensitive K channel mediated cerebrovasodilation after hypoxia/ischemia through upregulation of ERK MAPK.Tissue plasminogen activator-independent roles of neuroserpin in the central nervous system.Tissue plasminogen activator prevents white matter damage following stroke.Inflammatory Animal Model for Parkinson's Disease: The Intranigral Injection of LPS Induced the Inflammatory Process along with the Selective Degeneration of Nigrostriatal Dopaminergic Neurons.Salvinorin A pretreatment preserves cerebrovascular autoregulation after brain hypoxic/ischemic injury via extracellular signal-regulated kinase/mitogen-activated protein kinase in pigletsThe complexity of tissue-type plasminogen activator: can serine protease inhibitors help in stroke management?High levels of soluble VEGF receptor 1 early after trauma are associated with shock, sympathoadrenal activation, glycocalyx degradation and inflammation in severely injured patients: a prospective studyThe neurobiology of zinc in health and disease.Nitric oxide and zinc homeostasis in acute lung injury.Signaling, delivery and age as emerging issues in the benefit/risk ratio outcome of tPA For treatment of CNS ischemic disorders.Tissue plasminogen activator-mediated fibrinolysis protects against axonal degeneration and demyelination after sciatic nerve injury.Longitudinal changes in zinc transport kinetics, metallothionein and zinc transporter expression in a blood-brain barrier model in response to a moderately excessive zinc environmentRBC-coupled tPA Prevents Whereas tPA Aggravates JNK MAPK-Mediated Impairment of ATP- and Ca-Sensitive K Channel-Mediated Cerebrovasodilation After Cerebral PhotothrombosisStressed neurons protect themselves by a tissue-type plasminogen activator-mediated EGFR-dependent mechanism.uPA impairs cerebrovasodilation after hypoxia/ischemia through LRP and ERK MAPKPlasminogen mediates the atherogenic effects of macrophage-expressed urokinase and accelerates atherosclerosis in apoE-knockout miceTissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein.Inhibition of integrin alphavbeta3 prevents urokinase plasminogen activator-mediated impairment of cerebrovasodilation after cerebral hypoxia/ischemia.A comparison of Zn2+- and Ca2+-triggered depolarization of liver mitochondria reveals no evidence of Zn2+-induced permeability transitionRed blood cells-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia/ischemia through inhibition of ERK MAPK activationZinc-triggered induction of tissue plasminogen activator and plasminogen in endothelial cells and pericytes.Upregulation of zinc transporter 2 in the blood-CSF barrier following lead exposureBeta-amyloidolysis and glutathione in Alzheimer's disease.Pivotal role of tissue plasminogen activator in the mechanism of action of electroconvulsive therapy.Tissue-type plasminogen activator is a neuroprotectant in the mouse hippocampus.Coagulofibrinolytic Changes in Patients with Post-cardiac Arrest Syndrome.Editorial: The Role of the Plasminogen Activating System in Neurobiology.
P2860
Q26777261-8669FAF8-E4AB-4330-9F66-311C61315A74Q26777276-E26CE79A-39FF-4B99-AB31-97FB1C849C92Q26782904-B5509FFF-A5B5-40D4-A09C-3FE96E5D707FQ27329809-8036B420-1F18-46C3-921A-6594BB12FD99Q28488062-D7932563-DBC3-4890-A81C-6E7D459F72F5Q32063592-93A5A196-A030-47B3-9FF2-56A7434F7643Q33258227-A5909941-239C-44D0-BFBE-F39740C515C1Q33790610-0CF38A0A-9F26-4EEE-8180-60E2393AC4E7Q33823616-0E73F96A-D168-4D3F-B769-6A01873E5E1FQ33857787-1B2B3ED7-DD2C-45E6-9F95-0F2144A269C5Q33926785-903B07BF-5AAC-4CF2-832B-25217976D477Q33994910-CB8A6FE2-B4CE-40DF-8ABF-40BC9ABB83D4Q34461965-E0506208-3B7F-4343-815B-1A5D68A5BD20Q34570654-8874EEE4-9FDC-4073-B4B7-083653966306Q35160743-D8498D3A-C2A9-42CE-A4FF-644464117E13Q35213585-5C3FC75F-FD07-4185-B11D-7C869B84FB9BQ35687315-632B5614-F5A8-4F52-A763-2C22971FAAD8Q35799306-F464C950-3198-4B89-889B-7D44B1265C6BQ35842504-97DFAC69-C696-47FE-A6AB-23C6DFFBEF97Q35960425-378A4F19-7A74-4205-83F0-85179E50A0D8Q36126098-41667BB5-9F53-4259-9E30-871831C86579Q36284883-EC229B06-6C68-4371-940A-7FD467650307Q36307742-F57B96CA-4332-49C3-B48B-F1A1A7C733AEQ36327527-5DEBFB6B-5E18-4CB5-87B0-1E3DE6487B87Q36468222-F8AF326B-C936-4D2F-9D55-63963F80C7A2Q36748046-35506755-0225-43AE-8E19-5372CF07F4F8Q36751280-57CE80A1-7F54-45DE-ABCA-D0A401060ACBQ36948533-05913106-B990-45FD-A6CF-1380A5094F9CQ36964350-07D4E029-CD3A-4849-8CAE-461F14EE47B7Q36991072-DBF5C28B-4CCB-40AC-BF71-390A22F13D93Q37138982-13FCCBD1-6067-4030-822D-FC549F024FA0Q37274540-E4980046-BFD2-48E1-909E-8C1D0AA52AABQ37285884-79604D5A-7DF0-4366-B083-411A74C65ACCQ37500333-C71B6B0B-8A27-4D16-9A67-0D6112D09825Q37592271-544B87B9-1963-476F-913B-FFEC35A1AAE5Q38104717-B71AB1A2-F3B2-46F5-82A8-7BB14EF99C50Q38151373-82CF9867-67C3-4742-9FE7-AE9E56E92CF9Q40795719-524F6150-372A-4FB9-8679-4208AB4F3340Q42369766-FC4C85EF-9D0B-4AC7-B373-7742F4257DC3Q42388151-3EE399D2-2299-4094-814C-CE42267C9C60
P2860
Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator
@ast
Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator
@en
Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator
@nl
type
label
Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator
@ast
Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator
@en
Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator
@nl
prefLabel
Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator
@ast
Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator
@en
Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator
@nl
P2093
P3181
P1433
P1476
Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator
@en
P2093
P304
P3181
P356
10.1126/SCIENCE.284.5414.647
P407
P577
1999-04-23T00:00:00Z